DALLAS, Jan. 10, 2014 /PRNewswire/ -- Macrocyclics, Inc. (an AREVA Med company) announced today the introduction of four new products that will expand PET imaging applications with copper-64 and gallium-68 using NOTA-based chelating platforms. In addition, a new serotonin-based DOTA conjugate offers the potential to image serotoninergic neurotransmission using a radioisotope or with gadolinium by magnetic resonance imaging (MRI).
(Logo: http://photos.prnewswire.com/prnh/20130523/DA20136LOGO)
Please visit www.macrocyclics.com for detailed information.
MORE ABOUT MACROCYCLICSMacrocyclics is the global leader in high performance chelating agent technologies for medicine since 1995. Our team at Macrocyclics is dedicated to providing clients with both established and innovative chelating agents and services to meet the challenges of molecular imaging and nuclear medicine. www.macrocyclics.com
MORE ABOUT AREVA MED AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 (²¹²Pb), a rare metal that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: http://arevamed.areva.com/ or www.targetedtrials.com.
Macrocyclics Garry KieferT: +1 972 250 2248 F: +1 972 250 2245 info@macrocyclics.com
AREVA Med Alison TiseT: +1 301 841 1673 F: +1 434 382 4250 alison.tise@areva.com
